Pro-inflammatory cytokines and their receptors in chronic heart failure: do they really matter?

Area of Science:

• Cardiology
• Immunology
• Pathophysiology

Background:

• Chronic heart failure (CHF) management has significantly advanced, with neurohormonal pathway antagonists as a cornerstone therapy.
• A potential therapeutic ceiling for neurohormonal antagonists has been approached, necessitating exploration of alternative mechanisms.

Purpose of the Study:

• To highlight the emerging role of low-grade inflammation and immune activation in the pathophysiology of moderate to severe CHF.
• To discuss the implications of elevated pro-inflammatory cytokines in CHF.
• To review the current status of immune modulation as a therapeutic strategy for CHF.

Main Methods:

• Review of current literature on CHF pathophysiology and treatment.
• Analysis of the role of inflammatory markers and immune responses in CHF.
• Evaluation of the efficacy of anti-cytokine therapies in CHF.

Main Results:

• Patients with moderate to severe CHF exhibit a low-grade inflammatory status with increased circulating and tissue pro-inflammatory cytokines.
• Immune activation appears to contribute to both cardiac and peripheral manifestations of CHF.
• Targeted anti-cytokine treatments have not been successful in CHF patients.

Conclusions:

• Inflammation and immune activation are critical pathophysiological components of CHF, beyond neurohormonal imbalances.
• While direct anti-cytokine therapy has failed, immune modulation remains a promising area for future CHF research and treatment development.